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Abstract 
Background: S-nitrosylation (SNO), a prototypic redox-based posttranslational 
modification, is involved in the pathogenesis of cardiovascular disease. The aim of this 
study was to determine the role of S-nitrosylation of muscle LIM protein (MLP) in 
myocardial hypertrophy, as well as the mechanism by which SNO-MLP modulates 
hypertrophic growth in response to pressure overload. 
Methods: Myocardial samples from patients and animal models exhibiting myocardial 
hypertrophy were examined for SNO-MLP level using biotin-switch methods. 
S-nitrosylation sites were further identified through liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Denitrosylation of MLP by the mutation of nitrosylation sites 
or overexpression of S-nitrosoglutathione reductase (GSNOR) was used to analyze the 
contribution of SNO-MLP in myocardial hypertrophy. Downstream effectors of SNO-MLP 
were screened through mass spectrometry (MS) and confirmed by 
co-immunoprecipitation. Recruitment of toll-like receptor 3 (TLR3) by SNO-MLP in 
myocardial hypertrophy was examined in TLR3 small interfering RNA 
(siRNA)-transfected neonatal rat cardiomyocytes (NRCMs) and in TLR3 knockout mouse 
model.  
Results: SNO-MLP level was significantly higher in hypertrophic myocardium from 
patients and in spontaneously hypertensive rats and mice subjected to transverse aortic 
constriction (TAC). The level of SNO-MLP also increased in angiotensin II (Ang II) or 
phenylephrine (PE)-treated NRCMs. S-nitrosylated site of MLP at cysteine (Cys) 79 was 
identified by LC-MS/MS and further confirmed in NRCMs. Mutation of Cys79 significantly 
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3 
reduced hypertrophic growth in Ang II or PE-treated NRCMs and TAC mice. Reducing 
MLP S-nitrosylation level by overexpression of S-nitrosoglutathione reductase greatly 
attenuated myocardial hypertrophy. Mechanistically, MLP S-nitrosylation stimulated 
TLR3 binding to MLP in response to hypertrophic stimuli, and disrupting this interaction 
by downregulating TLR3 attenuated myocardial hypertrophy. SNO-MLP also increased 
the complex formation between TLR3 and receptor-interacting protein kinase 3 (RIP3). 
This interaction in turn induced NOD-like receptor pyrin domain containing 3 (NLRP3) 
inflammasome activation, thereby promoting the development of myocardial hypertrophy.  
Conclusions: Our findings revealed a key role of SNO-MLP in myocardial hypertrophy 
and demonstrated TLR3-mediated RIP3 and NLRP3 inflammasome activation as the 
downstream signaling pathway, which may represent a novel therapeutic target for 
myocardial hypertrophy and heart failure. 
 
Keywords: myocardial ypertrophy; S-nitrosylation; MLP; TLR3. 
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Clinical Perspective 
What is new? 
 We identified a new S-nitrosylated protein SNO-MLP in myocardial hypertrophy. 
 We showed that SNO-MLP contributes to myocardial hypertrophy through 
TLR3/RIP3 and NLRP3 inflammasome pathway. 
 We reported that the deficiency of S-nitrosylated MLP-governed TLR3 alleviates 
pathological myocardial hypertrophy. 
What are the clinical implications? 
 Pathological myocardial hypertrophy occurs in the various cardiovascular diseases, 
but to date, no therapies are available to arrest specifically the disease progression. 
 Therapeutic intervention for S-nitrosylation of MLP may be more effective in 
attenuating myocardial hypertrophy. 
 The cysteine 79 of MLP and TLR3 as downstream effector of SNO-MLP represent 
putative novel therapeutic targets in myocardial hypertrophy and pathological 
remodeling. 
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Non-standard Abbreviations and Acronyms 
SNO: S-nitrosylation 
MLP: muscle lim protein 
TLR3: Toll-like receptor 3 
GSNOR: S-nitrosoglutathione reductase  
NRCMs: neonatal rat cardiomyocytes 
TAC: transverse aortic constriction () 
Ang II: angiotensin II 
PE: phenylephrine  
RIP3: receptor-interacting protein kinase 3  
NLRP3: NOD-like receptor pyrin domain containing 3 
IL-1β: interleukin-1β 
 
 
Introduction 
Globally, there is a continuous increase in morbidity and mortality rates resulting from 
cardiovascular disease.1 Myocardial hypertrophy, occurring in hypertension and aortic 
stenosis, and the progression of stress-induced heart failure represent an independent 
risk factor for cardiac mortality;2 however, the underlying mechanisms of myocardial 
hypertrophy remain poorly defined, and treatment strategies specific to the pathological 
hypertrophy process have not been developed. 
Muscle LIM protein (MLP), belonging to LIM-only domain family, is located in the 
skeletal muscle and the myocardium.3 MLP has been widely reported as a scaffold 
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6 
protein, binding to other proteins through two zinc finger structure domains (LIM 
domains).4 The LIM domain may serve as a protein-binding interface.5 In cardiac 
myocytes, MLP is mainly located on the Z-lines of myofibrils and it interacts with many 
Z-line proteins, including T-cap/telethonin,6 calcineurin,7 histone deacetylase 4 
(HDAC4),8 and α-actinin.9 Studies have shown that MLP plays central roles in the 
pathogenesis of myogenic differentiation, hypertrophy, and dilated cardiomyopathy.10-12 
MLP knockout mice develop heart failure,13 highlighting a critical role of MLP in cardiac 
homeostasis. Recent work however reported that the overexpression of MLP did not 
modulate myocardial hypertrophy and that total expression level of MLP was not altered 
in the myocardial hypertrophy.14 This discrepancy may stem from different 
post-translational modifications (PTMs) of MLP, rather than total MLP level per se, which 
may play a critical role in myocardial hypertrophic growth. 
PTMs represent a vital determining factor in modulating protein functions. Many 
groups, including ours, have shown that S-nitrosylation contributes to various 
cardiovascular diseases.15-18 S-nitrosylation is a reversible, covalent addition of nitric 
oxide (NO) moiety to cysteine thiols, forming S-nitrosoprotein (SNO-protein), which can 
regulate protein function and cellular signaling via altering protein conformation, 
enzymatic activity, protein–protein interactions, and cellular localization.19 Whether MLP 
could be S-nitrosylated and whether this specific PTM of MLP might contribute to 
myocardial hypertrophy, remain an open question.  
In the present study, we demonstrated that MLP S-nitrosylation, rather than MLP 
total protein level, plays a crucial role in myocardial hypertrophy. MLP modification 
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7 
enhanced MLP binding to toll-like receptor 3 (TLR3) and receptor-interacting protein 
kinase 3 (RIP3), which stimulate NOD-like receptor pyrin domain containing 3 (NLRP3) 
inflammasome activation and consequent caspase-1 and interleukin-1β (IL-1β) activation, 
ultimately promoting myocardial hypertrophy. The activation of inflammasome was 
identified in cardiomyocytes in pathological conditions. Further, inflammatory response 
plays an important role in regulating myocardial hypertrophy and heart failure20-22. Our 
data therefore identified S-nitrosylated MLP as a key regulator, which together with TLR3 
may serve as putative therapeutic targets in treating pathological myocardial hypertrophy 
and heart failure. 
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Methods 
The data that support the findings of this study are available from the corresponding 
author on reasonable request. 
 
Human myocardium samples 
Human myocardium samples were collected during cardiac valve replacement surgical 
procedures and were classified into samples without myocardial hypertrophy and 
myocardial hypertrophy samples according to prior echocardiographic findings 
(Supplemental Table 1). The study conformed to the principles outlined in the 
Declaration of Helsinki. The study protocol was approved by the ethics committee of the 
First Affiliated Hospital of Xiamen University (approval no. KYZ-2014-007). Written 
informed consent was obtained from all the patients.  
Experimental animals  
Male spontaneously hypertensive rats (SHRs) and Wistar Kyoto rats of 12 weeks old 
were obtained from Shanghai SLAC Laboratory Animal Co. Ltd (Shanghai, China). 
Toll-like receptor 3 (TLR3) knockout (KO) mice were acquired from Dr. Liu Jin and Chen 
Chan (Department of Anesthesiology and Translational Neuroscience Center, West 
China Hospital, Sichuan University). The coding region of MLP cDNA was purchased 
from Hanbio Biotechnology (Shanghai, China). The plasmid construct encoding the 
complete mouse MLP gene was used to produce AAV9-MLP vectors including 
AAV9-MLP WT and AAV9-MLP C79A. This recombinant adeno-associated virus 9 (AAV9) 
was generated in Li Dali laboratory (Shanghai Key Laboratory of Regulatory Biology, 
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9 
Institute of Biomedical Sciences and School of Life Sciences, East China Normal 
University). Wild-type male mice of 4 weeks old (C57BL/6J) were intravenously injected 
with AAV9-GFP, AAV9-MLP WT, and AAV9-MLP C79A (5 X 1011 GC/mouse). At 8 weeks 
after injection, mice were sacrificed and MLP overexpression in the heart was confirmed 
by western blotting. The AAV9 system was also used in determining the overexpression 
of S-nitrosoglutathione reductase (GSNOR) in mice hearts. MLP C79A Knock-in mouse 
line was generated using CRISPR/Cas9 genome editing technology and maintained in 
C57BL/6 background.  
Mouse model of myocardial hypertrophy was generated by thoracic aortic 
constriction (TAC) surgery on 8 weeks old wild type, TLR3 knockout mice, and AAV9 
virus-injected mice. Surgeries were performed according to previously published 
protocols and sham surgeries were performed in the same way but without constriction of 
the aorta.23 Four or eight-week-old male C57BL/6J mice were housed in the Animal Core 
Facility of Nanjing Medical University with 12-hour light/dark cycles and were fed a 
standard chow diet. All experiments were conducted randomly, and investigators were 
blinded to the treatment groups. All animal experiments were approved by the Animal 
Care and Use Committee of Nanjing Medical University and were conducted in 
accordance with the National Institutes of Health (NIH) Guide for the Care and Use of 
Laboratory Animals (approval no. NJMU-1403073/1403076).  
Analysis of protein S-nitrosylation by biotin switch assay 
A modified biotin switch assay was performed as previously described.15 Specific 
nitrosylated proteins were detected using standard immunoblot techniques. MLP 
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S-nitrosylation was determined by biotin-switch assay using S-nitrosylated protein 
detection kit (Cayman Chemical, Ann Arbor, USA), according to the manufacturer’s 
instructions. Briefly, free thiols on proteins were blocked using a blocking agent. We 
lysed and collected cell or tissue proteins with a blocking buffer to block the free thiols 
and then S-nitrosothiols were reduced to yield free thiols with reducing buffer ascorbic 
acid (Vitamin C, Vc) and were covalently labeled biotin using labeling buffer. The 
negative control was not given reducing buffer to reduce nitrosothiols. Subsequent 
detection using avidin-coupled reagents was used to localize the biotinylated proteins. 
The biotinylated proteins were incubated overnight at 4C with Pierce™ NeutrAvidin™ 
Plus UltraLink™ Resin (ThermoFisher, San Jose, USA) and bound proteins were eluted 
by boiling at 95 C with loading buffer and analyzed by SDS-PAGE. 
Mass spectrometry determination of S-nitrosylated sites 
Liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis was 
performed by the Institute of Biophysics, Chinese Academy of Sciences as previously 
described.24 Purified heart proteins from spontaneously hypertensive rats (SHRs)/Wistar 
Kyoto (WKY) rats and transverse aortic constriction (TAC)/Sham mice were blocked 
using N-ethylmaleimide (NEM) and labeled with biotin-maleimide.25 Biotinylated proteins 
were then trypsinized (using a 1: 50 ratio of protein: trypsin) for 16 h and were purified 
with streptavidin-agarose for LC-MS/MS analysis. Peptides were separated using 
NanoLC 1D Plus system. Eluting peptide cations were ionized by nanospray and were 
analyzed using LTQ-Orbitrap XL mass spectrometer (Thermo Scientific). MS/MS spectra 
were searched against UniProt rat/mouse proteome database using SequestHT. 
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Statistics 
Continuous variables were summarized as mean ± standard error of the mean (SEM). 
For the comparison of the means between two groups, unpaired 2-sided Student's t-test 
was used when the data showed equal variance test; otherwise, the t-test assuming 
unequal variance was performed. For the comparisons among more than two groups, 
Brown-Forsythe test was firstly used to evaluate the homogeneity of variance. If the data 
did pass the equal variance test, one-way ANOVA analysis was used followed by 
post-hoc analysis using Bonferroni method to adjust for multiple comparisons; otherwise, 
Welch ANOVA test was performed followed by post-hoc analysis using Tamhane’s T2 
method. Statistical significance level was set at 0.05 (two-sided) unless otherwise stated. 
Statistical results and the corresponding methods were presented in the figure legends 
as well. All the statistical analyses were performed with SPSS Version 25 software 
(SPSS Inc., Chicago, IL, USA), and the graphs were generated using GraphPad Prism 8 
(La Jolla, CA, USA). 
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Results 
S-nitrosylated MLP, but not total MLP, is elevated in human and murine 
hypertrophic heart 
To identify the role of S-nitrosylation in myocardial hypertrophy, a non-biased screening 
was performed on heart tissues from thoracic aortic constriction (TAC) mice and 
spontaneously hypertensive rats (SHR) using biotin switch procedures and LC-MS/MS 
analysis. We identified 126 S-nitrosylated proteins in TAC mouse heart and 79 
S-nitrosylated proteins in SHR rat heart (Supplemental Figure 1). Comparison between 
the two datasets identified 32 overlapping targets. MLP is one of the highly S-nitrosylated 
proteins (Supplemental Figure 1).  
To determine the role of SNO-MLP in the development of myocardial hypertrophy, 
we assessed MLP S-nitrosylation level in the myocardial samples from patients 
undergoing cardiac valve surgery. MLP S-nitrosylation, but not total MLP levels, were 
significantly higher in hypertrophic heart samples, compared to non-hypertrophic 
samples (Supplemental Table 1, Figure 1A). Consistent with these human data, 
SNO-MLP, but not total MLP, was increased in the hearts of TAC mice (Figure 1B) and 
SHR rats (Figure 1C), compared to corresponding controls. In NRCMs cultures, we 
treated cells with Ang II (Angiotensin II) or PE (phenylephrine) to mimic hypertrophic 
conditions and we found higher SNO-MLP levels with unchanged levels of total MLP 
protein by these hypertrophic stimuli (Figure 1D-1E). Thus, these data suggest that 
SNO-MLP level, rather than total MLP level, is elevated during myocardial hypertrophy. 
Cysteine 79 is the S-nitrosylation site of MLP in myocardial hypertrophy 
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13 
We further identified the specific SNO-site(s) on MLP. MLP has 16 cysteine residues that 
could potentially be nitrosylated. To explore the specific SNO-site(s) of MLP in 
myocardial hypertrophy, we employed LC-MS/MS technology. Only Cys79 was identified 
as modified in the heart tissues from both TAC mice and SHR rats (Figure 2A, 
Supplemental Figure 2). We next transfected Ad-GFP, Ad-MLP WT, and Ad-MLP C79A 
into NRCMs to detect the level of MLP S-nitrosylation. The transfection efficiency was 
determined as approximately 80% using adenovirus-encoding GFP (Supplemental 
Figure 3). We found that the expression of exogenous MLP significantly increased while 
the expression of endogenous MLP was suppressed after transfection of Ad-MLP WT 
and Ad-MLP C79A, and the level of total SNO-MLP (exogenous and endogenous) was 
similar in GFP and WT groups (Figure 2B). Moreover, Ang II significantly promoted the 
level of S-nitrosylation of exogenous Flag-MLP, but Cys79 mutation inhibited Ang 
II-induced S-nitrosylation of exogenous Flag-MLP (Figure 2B). These results suggest 
that Cys79 is the S-nitrosylation site of MLP in myocardial hypertrophy. Subsequently, we 
administered Ad-GFP, Ad-MLP WT, or Ad-MLP C79A in Ang II or PE-treated NRCMs. 
Compared to WT-MLP, C79A significantly attenuated the elevation of atrial natriuretic 
peptide (Anp), brain natriuretic peptide (Bnp), and β-myosin heavy chain (β-mhc) levels 
and the increase in cell surface area (Figure 2C-2D, and Supplemental Figure 4). 
These data show that Cys79 is the S-nitrosylation site of MLP that may govern cardiac 
hypertrophic growth. 
We next used the siRNA approach to exclude the interference of endogenous MLP. 
We measured the siRNA efficiency by western blotting, and the silencing efficiency was 
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14 
up to 75% (Supplemental Figure 5A). We designed 3 independent siRNAs against MLP. 
Both siRNA1 and siRNA2 decreased the level of endogenous MLP, but only siRNA2 
(siRNA against 5’UTR of rat MLP) decreased endogenous MLP protein level with no 
effect on exogenous MLP (Supplemental Figure 5B-5C). Next, NRCMs were 
transfected with siRNA2 to silence endogenous MLP and then transfected with Ad-MLP 
WT or Ad-MLP C79A to overexpress exogenous MLP. RT-PCR analysis showed that we 
successfully reduced endogenous MLP and overexpressed exogenous MLP 
(Supplemental Figure 5D). More importantly, excluding the interference of endogenous 
MLP, C79A mutant significantly attenuated the elevation of Anp, Bnp, and β-mhc (Figure 
2E). These data showed that the overexpression of a non-nitrosylatable form (C79A) of 
MLP prevents Ang II–induced myocardial hypertrophy and its associated indices, 
independent of the presence of endogenous MLP. 
 
Inhibition of MLP S-nitrosylation by Cys79 mutation attenuates TAC-induced 
myocardial hypertrophy 
To examine further the cardiac response of SNO-MLP in myocardial hypertrophy in vivo, 
we generated a knock-in mouse in which C79 of MLP was mutated to alanine (MLP 
C79A) using CRISPR/Cas9 technology (Supplemental Figure 6A-6B). MLP C79A 
mutant and wild type mice of 8 weeks old were subjected to TAC or sham surgery. As 
shown in Figure 3A, TAC surgery significantly increased SNO-MLP in wild-type group; 
however, in MLP C79A mutant mice, MLP S-nitrosylation was almost disappeared. The 
impact of MLP C79A mutant on myocardial hypertrophy was assessed by 
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15 
echocardiography. In TAC-induced hypertrophic hearts, fraction shortening (FS) was 
lower than in sham group, and C79A mutant alleviated TAC-induced cardiac dysfunction 
(Figure 3B). The results of interventricular septum (IVS) and left ventricular posterior 
wall thickness (LVPW) also showed that cardiac hypertrophic growth was significantly 
induced by TAC, and non-nitrosylated MLP group (C79A mutant) alleviated these 
increases (Figure 3C-3D, Supplemental Table 2). We further confirmed that C79A 
mutant mice attenuated the TAC-induced increase in left ventricular weight/tibia length 
(LVW/TL) ratio (Figure 3E). Hematoxylin-eosin staining measurement of heart 
cross-sectional area indicated the prevention of TAC-induced hypertrophy of 
cardiomyocytes by MLP C79A (Figure 3F). Thus, these results demonstrate that the 
inhibition of S-nitrosylation of MLP prevents TAC-induced myocardial hypertrophy and 
that MLP C79A mutation is protective against pressure overload-induced myocardial 
hypertrophy.   
We also used the exogenous overexpression of adeno-associated virus 9 (AAV9) to 
detect further the role of SNO-MLP in myocardial hypertrophy. AAV9-GFP, AAV9-MLP 
WT, and AAV9-MLP C79A were injected intravenously into mice to overexpress 
Flag-MLP in the heart, respectively (Supplemental Figure 7A-7B). The expression of 
exogenous MLP significantly increased, and endogenous MLP expression was 
suppressed after transfection of AAV9-MLP WT and AAV9-MLP C79A (Supplemental 
Figure 8A). TAC surgery significantly increased exogenous SNO-Flag-MLP in the 
AAV9-MLP WT group whilst C79A administration attenuated TAC-induced MLP 
S-nitrosylation (Supplemental Figure 8A). 
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We next evaluated the impact of inhibiting SNO-MLP at Cys79 on myocardial 
hypertrophy. Echocardiography indices of IVS and LVPW showed that cardiac 
hypertrophic growth was significantly induced by TAC, and non-nitrosylated MLP group 
(C79A mutant) alleviated this increase (Supplemental Figure 8B-8C, Supplemental 
Table 3). We further confirmed that C79A mutant attenuated TAC-induced increase in 
LVW/TL ratio (Supplemental Figure 8D). C79A mutant also alleviated TAC-induced 
cardiac dysfunction (Supplemental Figure 8E). Hematoxylin-eosin staining and wheat 
germ agglutinin measurement of heart cross-sectional area indicated the prevention of 
TAC-induced hypertrophy of cardiomyocytes by MLP C79A (Supplemental Figure 8F). 
Consistent with these findings, the induction of Anp and Bnp by TAC was markedly 
abrogated by MLP C79A (Supplemental Figure 9A-9B). Thus, these results 
demonstrate that inhibition of S-nitrosylation of MLP prevents pressure overload-induced 
myocardial hypertrophy. 
 
Denitrosylation of MLP by overexpression of GSNOR mitigates myocardial 
hypertrophy 
To investigate further the role of SNO-MLP in myocardial hypertrophy and the underlying 
mechanisms, we explored the upstream enzymes that regulate SNO-MLP. NO synthase 
(NOS) can enhance the level of S-nitrosylation. GSNOR and TRX can denitrosylate 
S-nitrosylation.26, 27 Therefore, we examined the expression of these enzymes in primary 
cells and animal models. 
In NRCMs treated with Ang II, SNO-MLP was significantly increased (Figure 1D) 
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whilst NOS and TRX protein levels were not changed (Supplemental Figure 10A); 
however, GSNOR was strongly suppressed (Figure 4A). GSNOR was also significantly 
decreased in the hearts of TAC mice (Figure 4B). These data indicate that GSNOR may 
be the major enzyme of S-nitrosylation, which is involved in myocardial hypertrophy, and 
decreased expression of GSNOR may promote SNO-MLP. To test this hypothesis, we 
transfected Ang II or PE-treated NRCMs with Ad-GSNOR. As expected, overexpression 
of GSNOR significantly suppressed Ang II or PE-induced S-nitrosylation of MLP (Figure 
4C, Supplemental Figure 10B). The overexpression of GSNOR also prevented Ang 
II-stimulated cardiomyocyte hypertrophy (Figures 4D-4E). To determine whether 
GSNOR is an upstream S-nitrosylating enzyme of MLP, siRNA against GSNOR was 
used to transfect NRCMs (Supplemental Figure 11A). We then infected the cells with 
Ad-MLP WT or Ad-MLP C79A to overexpress exogenous MLP. Ang II was administrated 
to induce hypertrophic growth. RT-PCR results showed that silencing GSNOR 
expression aggravated cardiomyocyte hypertrophic growth in Ang II induced 
hypertrophic model, and C79A mutant significantly attenuated this response in GSNOR 
silencing condition (Supplemental Figure 11B). In TAC mice, AAV9-GSNOR and the 
control virus AAV9-Vector were injected intravenously to overexpress GSNOR in the 
heart (Supplemental Figure 12A). Overexpression of GSNOR prevented the increase in 
cardiac MLP-SNO (Supplemental Figure 12B). Hypertrophic parameters including IVS, 
LVPW, LVW/TL ratio, and cardiac function parameter of FS was alleviated by GSNOR 
overexpression, in line with the phenotypes of mice with MLP C79A mutation 
(Supplemental Figure 12C-12G, Supplemental Table 4). Collectively, these data 
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indicate that decreasing MLP S-nitrosylation by either MLP Cys79 mutation or GSNOR 
upregulation prevents myocardial hypertrophy. 
TLR3 is the downstream effector of SNO-MLP in the regulation of myocardial 
hypertrophy 
To explore the downstream effector(s) of SNO-MLP in regulating myocardial hypertrophy, 
we further identified proteins that can directly bind SNO-MLP since MLP is a scaffold 
protein. NRCMs were transfected with WT-MLP and C79A-MLP adenovirus and 
subsequently treated with Ang II. We conducted a co-immunoprecipitation (co-IP) to 
enrich MLP protein and performed SDS-PAGE gel for silver staining. Next, we cut off five 
different strips of the gel to perform MS being unbiased. We identified TLR3 as a new 
MLP-binding protein (Figure 5A, Supplemental Figure 13). To confirm the MS results, 
co-IP experiments were performed on myocardial samples from patients undergoing 
cardiac valve surgery. The interaction between MLP and TLR3 was more prominent in 
hypertrophic hearts than non-hypertrophic samples (Figure 5B). In hypertrophic NRCMs 
and TAC mouse hearts, we found that MLP could indeed bound TLR3, and this binding 
was enhanced under hypertrophic conditions but attenuated by S-nitrosylation deficiency 
of MLP (MLP-C79A mutation), at both in vitro (Figure 5C) and in vivo (Figure 5D) levels, 
indicating that SNO modification of MLP can facilitate MLP binding to TLR3. 
To examine whether Cys79 is the binding site, we transfected Ad-MLP WT or 
Ad-MLP C79A into NRCMs to detect the interaction between TLR3 and MLP. The 
interaction between MLP and TLR3 was not changed (Supplemental Figure 14). These 
findings indicate that Cys79 on MLP may not be the binding site for TLR3 interaction. To 
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confirm further the protein interaction, we investigated the effects of TLR3 on binding to 
MLP by an in vitro binding assay. We found that the amount of TLR3 bound to MLP 
significantly increased in GSNO (nitric oxide donor; promoting S-nitrosylation)-treated 
group compared to non-nitrosylated MLP group (C79A mutant). As expected, no 
difference between WT and C79A mutant in non-GSNO group was detected for their 
binding to TLR3 (Supplemental Figure 15). Based on these findings, we conclude that 
SNO-MLP at Cys79 promotes TLR3 binding to MLP. 
To evaluate further the role of TLR3 in hypertrophy, we transfected NRCMs with 
siRNA against TLR3 (Supplemental Figure 16A). Silencing TLR3 significantly inhibited 
Ang II-induced cardiomyocyte hypertrophy, as indicated by fetal gene activation at both 
protein and mRNA levels (Figure 6A-6B, Supplemental Figure 16B-16C). To evaluate 
the consequences in vivo, we used TLR3-KO mice (Supplemental Figure 16D) to 
disrupt fully TLR3 binding to MLP and performed TAC surgery (Figure 6C). IVS, LVPW 
and LVW/TL ratio were all reduced in TLR3-KO-TAC mice compared to WT-TAC controls 
(Figure 6D-6F). And TLR3 deficiency alleviated TAC-induced cardiac dysfunction in 
TLR3-KO (Figure 6G, Supplemental Table 5). Collectively, these results suggest that 
S-nitrosylation of MLP promotes its binding to TLR3, and knocking down TLR3 to disrupt 
this interaction prevents pathological myocardial hypertrophy. Thus, TLR3 is a novel 
contributor to myocardial hypertrophy in response to elevated SNO-MLP and in the 
presence of hypertrophic stimulus. 
 
SNO-MLP facilitates myocardial hypertrophy through TLR3-mediated RIP3 binding 
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
20 
We next sought to identify the downstream effector(s) of SNO-MLP/TLR3 in the 
development of myocardial hypertrophy. In previous studies, TLR3 and RIP3 were 
expressed in cardiomyocytes,28, 29 and TLR3 has been reported to drive 
receptor-interacting RIP3 activation via the adaptor protein TIR domain-containing 
adapter-inducing interferon-β (TRIF) in programmed necrosis.30 
To determine whether this signaling pathway plays a role in myocardial hypertrophy, 
interaction of TLR3, RIP3, and TRIF was examined in Ang II-treated NRCMs. Co-IP 
experiments confirmed that, TLR3 bound MLP together with RIP3 and TRIF. Every 
protein component in this complex except TRIF was increased in Ang II-induced 
hypertrophy, compared to control cells (Figure 7A). Similar results were obtained in TAC 
myocardial hypertrophic model (Figure 7B). To test whether this complex formation is 
modulated by SNO-MLP, the co-IP experiments were repeated in Ang II-treated NRCMs 
transfected with Flag-tagged MLP-WT or MLP-C79A. S-nitrosylation deficient MLP 
(MLP-C79A mutant), significantly inhibited Ang II-induced complex formation (Figure 7C). 
In TAC mouse hearts, Cys79 mutation also mitigated TAC-induced increase of this 
complex (Figure 7D). These results indicate that the interaction of MLP, TLR3, and RIP3 
is enhanced in myocardial hypertrophy and this complex formation is upregulated by 
increased SNO-MLP level.  
NRCMs were transfected with siRNA against 5’UTR of rat MLP and then incubated 
with Ad-MLP WT or Ad-MLP C79A. In these MLP deficient cells, the increased formation 
of complex was prevented by MLP-C79A (Figure 7E). Considering that TLR3 activates 
programmed cell death via TRIF and RIP3 interaction, we performed flow cytometry 
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experiments to assess cell viability. We found that MLP S-nitrosylation did not affect cell 
survival of Ang II-treated NRCMs incubated with Ad-MLP WT or Ad-MLP C79A 
(Supplemental Figure 17). These data suggest that SNO-MLP enhances the complex 
formation of MLP, TLR3, and RIP3, but without any significant effect on myocardial cell 
death during hypertrophic growth. Thus, these findings indicate that MLP, TLR3, and 
RIP3 interaction is upregulated by SNO-MLP in myocardial hypertrophy. 
 
p65-NLRP3-IL-1β pathway is induced by TLR3 and RIP3 in SNO-MLP-mediated 
myocardial hypertrophy 
To examine further the downstream pathway of TLR3/RIP3 in SNO-MLP-mediated 
myocardial hypertrophy, we focused on the inflammatory signaling activated by TLR3. 
We detected several downstream targets of TLR3 in the inflammatory signaling pathway, 
including p65, TRIF, and IRF3. Here, only change in p65 activity was observed, and not 
TRIF or IRF3 (Figure 8A). Moreover, we found that NLRP3 inflammasome, which was 
the downstream action of p65, was also activated (Figure 8A). We therefore focused on 
p65-NLRP3-IL1 pathway in SNO-MLP regulated myocardial hypertrophy. The 
phosphorylation of p65 and NLRP3 was increased in myocardial hypertrophy, which was 
attenuated by S-nitrosylation deficiency of MLP (MLP-C79A mutation) (Figure 8A). To 
test whether SNO-MLP exaggerates NLRP3-mediated inflammasome formation, 
confocal microscopy revealed that MLP-C79A significantly attenuated Ang II-induced 
NLRP3 inflammasome formation (Figure 8B). 
To confirm the role of NLRP3 in the regulation of myocardial hypertrophy, we used 
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NLRP3 inhibitor or Si-RNA to suppress NLRP3. MCC950, the NLRP3 inhibitor, 
significantly reduced Ang II-induced NLRP3 inflammasome formation and myocardial 
hypertrophy (Supplemental Figure 18A-18D). Moreover, NLRP3 knockdown strongly 
decreased hypertrophic growth in NRCMs, reflecting from the suppression of the Ang 
II-induced increase in Anp and Bnp expression and myocardial hypertrophy 
(Supplemental Figure 19A-19D). Consistent with these findings, MLP-C79A reduced 
NLRP3 inflammasome activity as indicated by reduced IL-1β expression, Caspase-1 p20 
level and IL-1β secretion in vitro (Supplemental Figure 20A-20B). Similar results were 
found in TAC mice (Figure 8C). We also detected the activation of IL-1β in the 
myocardial samples of patients undergoing cardiac valve surgery. Activation of IL-1β was 
significantly increased in hypertrophic heart samples (Figure 8D). Thus, these results 
demonstrate that S-nitrosylated MLP activates p65-NLRP3-IL-1β axis in myocardial 
hypertrophy.  
Next, to investigate whether RIP3 and p65-NLRP3-IL-1β pathways play a crucial role 
in regulating myocardial hypertrophy, NRCMs were treated with inhibitors of caspase-1 
and RIP3 (VX-765 or GSK’872), respectively. We found that VX-765 and GSK’872 
largely attenuated hypertrophy as indicated by Anp, Bnp, and β-mhc mRNA expression 
(Supplemental Figure 21A-21C), implying that RIP3 and p65-NLRP3-IL-1β pathways 
are both crucial in regulating myocardial hypertrophy. Previous reports suggest that RIP3 
is associated with the upstream of NLRP3 inflammasome formation but the regulatory 
relationship induced by SNO-MLP is not defined31, 32. To determine the upstream and 
downstream relationship between RIP3 and NLRP3 inflammasome in 
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SNO-MLP-mediated myocardial hypertrophy, NRCMs were treated with GSK’872, a 
RIP3-inhibitor and NLRP3-IL-1β pathway was examined. RIP3 inhibition with GSK'872 
significantly suppressed Ang II-induced IL-1β secretion and expression, as detected by 
ELISA and western blotting (Supplemental Figure 21D-21E). In order to confirm the role 
of IL-1β in hypertrophy, we performed the experiment that the mice suffered with TAC 
surgery were treated with IL-1β neutralizing antibodies. Interestingly, IL-1β neutralizing 
antibodies prevented TAC–induced myocardial hypertrophy and cardiac dysfunction 
(Figure 8E-8F, Supplemental Figure 22A-22C, Supplemental Table 6). These results 
prove that anti-IL-1β treatment significantly attenuates the TAC-induced hypertrophy, and 
promotes the cardiac function. Thus, the data presented here suggest that SNO-MLP 
enhances MLP interaction with TLR3 and RIP3, thence activating p65-NLRP3 
inflammasome signaling cascade, thereby working in concert to promote IL-1β secretion 
and myocardial hypertrophic growth (Figure 8G).  
Discussion  
Our data demonstrate that MLP can be S-nitrosylated and that SNO-MLP is an important 
positive regulator in myocardial hypertrophy. We have shown that Cys79 is the critical 
site of MLP for S-nitrosylation in modulating pressure overload-induced myocardial 
hypertrophy. In addition, our results revealed that MLP interacts with TLR3, a process 
regulated by MLP S-nitrosylation and we presented convincing evidence for the role of 
TLR3 in the development of myocardial hypertrophy. These data highlight a novel 
pathway in the development of myocardial hypertrophy, which may prove amenable to 
therapeutic intervention. 
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Although S-nitrosylation of many cardiac proteins has been reported in myocardial 
remodeling and heart failure,33 the role of protein S-nitrosylation in modulating 
myocardial hypertrophy has hitherto been unclear. Our findings revealed the central role 
of protein S-nitrosylation in hypertrophic signaling in the myocardium. We demonstrated 
that S-nitrosylation of MLP is increased in human and rodent hypertrophic hearts. MLP 
has 16 cysteine residues, however only the mutation of Cys79 decreases the level of 
SNO-MLP and functionally regulates hypertrophy. While there may be multiple cysteine 
residues in the protein that can be modified, not all of these are involved in pathological 
cardiac remodeling. These data suggest that the identification of specific sites of SNO 
modification may be crucial to provide specific therapeutic targets. 
To define the role of MLP SNO modification in myocardial hypertrophy, we used 
different approaches to modulate the level of SNO modification. In addition to mutate 
SNO-MLP cysteine site, we explored the enzymes that regulate SNO modification. We 
found that hypertrophic stimuli specifically decreased GSNOR expression.34, 35 As a 
denitrosylation protease, GSNOR has been implicated in many biological processes.35-39 
However, the mechanism by which GSNOR is downregulated in myocardial hypertrophy 
remains unknown. Emerging evidence suggests that NF-B binds to the promoter of 
GSNOR and activates the transcription during neuronal differentiation.40 We speculate 
that GSNOR may be similarly regulated by certain transcription factors in the presence of 
hypertrophic stimuli. 
Members of TLR family participate in multiple biological processes, such as immune 
response, differentiation, and cell survival. Recently, TLR4 has been reported to promote 
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pressure overload-induced myocardial hypertrophy through NF-B and TLR9.41, 42 As 
with TLR4 and TLR9, TLR3 is expressed in cardiomyocytes and it stimulates NF-B 
activity, but little is known about its role in the heart. In our study, hypertrophic stimulation 
promoted TLR3 binding to MLP. Knockdown of TLR3 in response to Ang II decreased the 
hypertrophy of cardiomyocytes. Similar results were found in TLR3 knockout mice 
subjected to TAC. Our study therefore provides the first evidence that increased 
interaction between MLP and TLR3 by hypertrophic stimulation is dependent on 
S-nitrosylation of MLP and that TLR3 is a positive regulator of myocardial hypertrophy. 
Meanwhile, S-nitrosylated deficiency for MLP prevented TAC-induced hypertrophy in 
MLP C79A mutant mice. Interestingly, AAV-MLP C79A also suppressed TAC-induced 
hypertrophy, suggesting that it could be a novel strategy using AAV-MLP C79A for 
hypertrophy treatment. In the immune system, dsRNA is the only recognized activator of 
TLR3.43 However, in the heart, we found that SNO-MLP activates TLR3 and its 
downstream effectors in response to hypertrophic stimuli. Previous work has shown that 
TLR3 or TLR4 directly activates programmed cell death through TRIF and RIP3.44 
Furthermore, TLR3 signaling may lead to distinct cellular outcomes triggered by TRIF via 
C-terminal RHIM domain interaction with RIP3, followed by activation of NF-B and 
initiation of apoptosis via caspase-8.45 In our study, SNO-MLP enhanced the complex 
formation of MLP, TLR3, and RIP3, but without any significant effect on myocardial cell 
death during hypertrophy. Further, RIP3 activated NLRP3-dependent inflammasome and 
contributed to myocardial hypertrophy. Our data indicate that, in a heart where 
hypertrophy has not progressed into heart failure, activation of RIP3 does not cause 
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cardiomyocyte death, but rather stimulates p65-NLRP3 NLRP3-dependent 
inflammasome pathway in the development of myocardial hypertrophy.29, 46 
Our data show that in SNO-MLP mediated myocardial hypertrophy, p65-NLRP3 
pathway is activated, which induces IL-1β secretion. Recently, a series of clinical trials 
provided evidence that IL-1β neutralizing antibody therapy is beneficial in cardiovascular 
diseases.47, 48 The Canakinumab Anti-inflammatory Thrombosis Outcome Study 
(CANTOS) showed that post-myocardial infarction subjects treated with IL-1β antibody 
showed reduced inflammation and cardiovascular event rates.49 In a dition, the 
administration of IL-1β neutralizing antibody in ApoE-/- mice decreased overall plaque 
burden.50 These results confirm IL-1β neutralizing antibody as a promising therapy for 
ischemic cardiovascular disease. Our results indicate that IL-1β plays an essential role in 
promoting myocardial hypertrophy, and that IL-1β neutralizing antibody suppresses 
TAC-induced myocardial hypertrophy, indicating that it is potential for IL-1β neutralizing 
antibody to treat with myocardial remodeling and heart failure.  
In conclusion, our study provides evidence that S-nitrosylation of MLP at Cys79 
enhances interaction with TLR3 and RIP3, which activates TLR3/RIP3 signaling to 
promote myocardial hypertrophy. This work therefore highlights a novel role of MLP 
S-nitrosylation in myocardial hypertrophy. Targeting SNO-MLP at Cys79 may prove to be 
a novel strategy in treating pathological myocardial hypertrophy and heart failure in the 
future. 
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Figure legends 
Figure 1. S-nitrosylated MLP but not total MLP is significantly higher in myocardial 
hypertrophy.  
A. Representative images for western blotting analysis of SNO-MLP expression in human 
samples from non-hypertrophic (N = 10) and hypertrophic myocardial tissues (N = 10). 
Protein expression was quantified and normalized to total MLP or GAPDH.  
B. SNO-MLP, total MLP and GAPDH expression in the myocardial tissues of mice at 4 
weeks after sham or TAC operation. Protein expression was quantified and normalized to 
total MLP or GAPDH (N = 6 per group).   
C. SNO-MLP, total MLP and GAPDH expression in the myocardial tissues of WKY or SHR 
rats. Protein expression was quantified and normalized to total MLP or GAPDH (N = 5 per 
group).  
D. Western blotting analysis of S-nitrosylation of MLP expression in Ang II (1 μM) treated 
NRCMs for 24 h (N = 6 independent experiments).  
E. Western blotting analysis of S-nitrosylation of MLP expression in PE (50 μM) treated 
NRCMs for 24 h (N = 5 independent experiments).  
**, P < 0.01; ***, P < 0.001 (A to C, t-test; D and E, t-test assuming unequal variance). NS: not 
significant. SNO-MLP: S-nitrosylation of muscle LIM protein; TAC: transverse aortic 
constriction; WKY: Wistar Kyoto rat; SHR: spontaneously hypertensive rat; Ang II: 
Angiotensin II; PE: phenylephrine; NRCMs: neonatal rat cardiomyocytes; -Vc: Without giving 
reducing buffer ascorbic acid (Vitamin C, Vc) to reduce the nitrosothiols; the negative control 
of biotin-switch method. 
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Figure 2. Cysteine 79 is the MLP S-nitrosylation site in myocardial hypertrophy. 
A. Representative LC-MS/MS spectra showing target modified peptide fragmentation 
(Cys79). LC-MS/MS scan of SNO sites of MLP in the myocardial tissues from TAC mice.  
B. Western blotting analysis detected S-nitrosylation of endogenous and exogenous 
SNO-MLP and total MLP levels after Ang II (1 μM, 24 h) incubation in NRCMs transfected 
with GFP, flag-tagged MLP-WT or C79A mutant for 24 h (N = 5 independent experiments).  
C. NRCMs were transfected with Ad-GFP, Ad-MLP-WT or Ad-MLP-C79A and subsequently 
treated with PBS or Ang II. The levels of Anp, Bnp and β-mhc mRNA expression were 
detected (N = 5-6 independent experiments).  
D. Representative images of NRCMs stained with α-actinin (red). NRCMs were transfected 
with Ad-GFP, Ad-MLP-WT or Ad-MLP-C79A and subsequently treated with PBS or Ang II for 
24 h (N = 3 independent experiments). 
E. After knockdown of endogenous MLP, NRCMs were transfected with Ad-MLP-WT or 
Ad-MLP-C79A and treated with Ang II. The levels of Anp, Bnp and β-mhc mRNA expression 
were determined by RT-PCR (N = 6 independent experiments).  
The comparisons with stars represent statistically significant after adjustment for multiple 
comparison (*, P < 0.05; **, P < 0.01; ***, P < 0.001; B (top), t-test assuming unequal variance; 
B (bottom), C to E, one-way ANOVA with Bonferroni post-hoc test). ND: not detected; 
LC-MS/MS: liquid chromatography-tandem mass spectrometry; Anp: atrial natriuretic peptide; 
Bnp: brain natriuretic peptide; β-mhc: β-myosin heavy chain. Scale bar = 50 μm in D. 
 
Figure 3. A knock-in mutation at Cysteine 79 of MLP attenuates TAC-induced 
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myocardial hypertrophy 
A. Biotin-switch and western blotting analyses of SNO-MLP and total MLP levels following 
sham or TAC operation in WT- or MLP-C79A-mutation mice.  
B. FS values were presented in WT- or MLP-C79A-mutation mice with sham or TAC operation.  
C. IVS values were measured after sham or TAC operation in WT- or MLP-C79A-mutation mice.  
D. LVPW values were analyzed after sham or TAC operation in WT- or MLP-C79A-mutation mice.  
E. LVW/TL ratios were calculated following sham or TAC operation in WT- or MLP-C79A-mutation 
mice.  
F. Histological sections of myocardial tissues from WT- or MLP-C79A-mutation mice with sham or 
TAC surgery were stained with hematoxylin & eosin (H&E; second and third rows; A-F: N = 7 per 
group).  
The comparisons with stars represent statistically significant after adjustment for multiple 
comparison (**, P < 0.01; ***, P < 0.001; A, t-test assuming unequal variance; B to F, one-way 
ANOVA with Bonferroni post-hoc test). ND: not detected; NS: not significant. IVS: 
interventricular septum; LVPW: left ventricular posterior wall thickness; LVW/TL: left 
ventricular weight/tibia length; FS: fractional shortening. Scale bar = 200 μm in the second 
row of F; Scale bar = 100 μm in the third row of F.   
 
Figure 4. Denitrosylation of MLP by GSNOR overexpression mitigates myocardial 
hypertrophy.  
A. Western blotting analysis of GSNOR in PBS- or Ang II-treated NRCMs (N = 6 
independent experiments).  
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B. Western blotting analysis of GSNOR in myocardial tissues from sham or TAC operated 
mice (N = 6 each group).   
C. Representative biotin-switch assay and western blotting analyses of S-nitrosylated MLP 
in NRCMs overexpressing GSNOR (Ad-GSNOR) or control adenovirus (Ad-PDC) with or 
without Ang II treatment (N = 6 independent experiments).  
D. Representative images of NRCMs stained with α-actinin (red). NRCMs were treated with 
Ad-GSNOR or Ad-PDC and subsequently incubated with PBS or Ang II (N = 3 independent 
experiments). 
E. NRCMs were treated with Ad-GSNOR or Ad-PDC and subsequently incubated with PBS 
or Ang II. The mRNA levels of Anp, Bnp and β-mhc expression were detected with RT-PCR 
(N = 5 independent experiments). 
The comparisons with stars represent statistically significant after adjustment for multiple 
comparison (*, P < 0.05; **, P < 0.01; ***, P < 0.001; A, t-test; B, t-test assuming unequal 
variance; C, Welch ANOVA with Tamhane’s T2 post-hoc test; D and E, one-way ANOVA with 
Bonferroni post-hoc test). ND: not detected. Scale bar = 50 μm in D. 
 
Figure 5. TLR3 is downstream of SNO-MLP in the regulation of myocardial 
hypertrophy.  
A. Immunoprecipitation and mass spectrometry assays showing the binding between TLR3 
and MLP in NRCMs lysates. MLP-Flag was overexpressed in Ang II-treated cardiomyocytes. 
The interaction proteins with MLP were immunoprecipitated by Flag antibody.  
B. Representative co-immunoprecipitation analysis of MLP and TLR3 in human samples 
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43 
from non-hypertrophic and hypertrophic hearts (N = 5 per group).  
C. Representative co-immunoprecipitation analysis of MLP and TLR3. NRCMs were 
transfected with Ad-MLP WT or Ad-MLP C79A, and subsequently treated with PBS or Ang II 
(N = 5 independent experiments). 
D. Representative co-immunoprecipitation analysis of MLP and TLR3 in myocardial tissues 
from mice administrated with AAV9-MLP-WT or AAV9-MLP-C79A and subsequently 
subjected to sham or TAC operation (N = 4 independent experiments).  
The comparisons with stars represent statistically significant after adjustment for multiple 
comparison (*, P < 0.05; B, t-test assuming unequal variance; C, one-way ANOVA with 
Bonferroni post-hoc test; D, Welch ANOVA with Tamhane’s T2 post-hoc test). ND: not 
detected. 
 
Figure 6. Decreasing of TLR3 expression alleviates the myocardial hypertrophy.  
A. Pro-ANP, BNP and TLR3 protein levels were detected in TLR3-knockdown NRCMs 
incubated with PBS or Ang II (N = 7 independent experiments). 
B. The mRNA levels of Anp and Bnp in TLR3-knockdown NRCMs incubated with PBS or 
Ang II (N = 9 independent experiments). 
C. Heart images of Tlr3-/- or wild type mice suffered with sham or TAC operation.  
D. IVS values were measured in Tlr3-/- or wild type mice following sham or TAC operation. 
E. LVPW values were analyzed in Tlr3-/- or wild type mice suffered with sham or TAC 
operation.  
F. LVW/TL ratios were calculated in Tlr3-/- or wild type mice suffered with sham or TAC 
 Dis
cla
im
er:
 Th
e m
an
us
cri
pt 
an
d i
ts 
co
nte
nts
 ar
e
co
nfi
de
nti
al,
 in
ten
de
d f
or 
jou
rna
l re
vie
w p
urp
ose
s
 
 
 
 
 
 
 
 
 
 
 
on
ly,
 an
d n
ot 
to 
be
 fu
rth
er 
dis
clo
se
d.
44 
operation.  
G. FS values were presented in Tlr3-/- or wild type mice suffered with sham or TAC operation. 
Tlr3-/- mice with sham group, N = 8; wild type mice with sham group, N = 8; Tlr3-/- mice with 
TAC group, N = 9; wild type mice with TAC group, N = 9. The comparisons with stars 
represent statistically significant after adjustment for multiple comparison (*, P < 0.05; **, P < 
0.01; ***, P < 0.001; A, B, D, E and G, one-way ANOVA with Bonferroni post-hoc test; F, 
Welch ANOVA with Tamhane’s T2 post-hoc test).  
 
Figure 7. S-nitrosylation of MLP enhances complex formation among MLP, TLR3 and 
RIP3. 
A. Co-immunoprecipitation analysis of TLR3, MLP, RIP3 and TRIF in NRCMs treated with 
PBS or Ang II (N = 5 independent experiments). 
B. Co-immunoprecipitation analysis of TLR3, MLP, RIP3 and TRIF in myocardial tissues 
from sham or TAC operation mice (N = 4 independent experiments).  
C. Co-immunoprecipitation analysis of exogenous MLP, TLR3, RIP3 and TRIF in NRCMs 
infected with Ad-MLP- WT or Ad-MLP-C79A and subsequently treated with PBS or Ang II. (N 
= 6 independent experiments). 
D. Co-immunoprecipitation analysis of exogenous MLP, TLR3, RIP3 and TRIF in myocardial 
tissues from sham or TAC-operated mice administrated with AAV9-GFP, flag-tagged 
AAV9-MLP-WT-or AAV9-MLP-C79A (N = 5 independent experiments). 
E. NRCMs were transfected with Ad-MLP WT or Ad-MLP C79A after MLP SiRNA 
transfection and subsequently treated with PBS or Ang II. Representative 
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co-immunoprecipitation analysis of exogenous MLP, TLR3, RIP3 and TRIF in NRCMs (N = 7 
independent experiments). 
The comparisons with stars represent statistically significant after adjustment for multiple 
comparison (*, P < 0.05; **, P < 0.01; ***, P < 0.001; A and B, t-test assuming unequal variance; 
C to E, one-way ANOVA with Bonferroni post-hoc test). NS: not significant. Exo-MLP: 
exogenous MLP. 
 
Figure 8. p65/NLRP3 is downstream of TLR3 in the regulation of myocardial 
hypertrophy.  
A. NRCMs were transfected with Ad-MLP-WT or Ad-MLP-C79A and subsequently treated 
with PBS or Ang II. Western blotting assay detected the levels of p-p65, p65, TRIF, p-IRF3, 
IRF3, NLRP3 and GAPDH expression in NRCMs (N = 3 independent experiments). 
B. NRCMs were transfected with Ad-MLP-WT or Ad-MLP-C79A and subsequently treated 
with PBS or Ang II. Representative images of DAPI (blue), NLRP3 (red) and F-actin (green) in 
NRCMs were presented.  
C. Western blotting analysis of Caspase-1, Caspase-1 p20, pro-IL-1β, IL-1β and GAPDH 
expression in my cardial tissues from TAC mice administrated with flag-tagged 
AAV9-MLP-WT or AAV9-MLP-C79A (N = 6 independent experiments).  
D. Western blotting analysis of pro-IL-1β, IL-1β and tubulin expression in human samples 
from non-hypertrophic (N = 5) and hypertrophic hearts (N = 5). 
E. IVS values were measured anti-IgG-or anti-IL-1β antibodies treatment in sham or 
TAC-operated mice. 
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F. LVPW values were analyzed in anti-IgG-or anti-IL-1β antibodies treatment in sham or 
TAC-operated mice (E-F: N = 7 per group).  
G. Working model of SNO-MLP-induced myocardial hypertrophy through its interaction with 
TLR3 and RIP3, with subsequent activation of the p65-NLRP3 inflammasome and IL-1β 
secretion. The comparisons with stars represent statistically significant after adjustment for 
multiple comparison (*, P < 0.05; **, P < 0.01; ***, P < 0.001; A, C, E and F, one-way ANOVA 
with Bonferroni post-hoc test; D, t-test assuming unequal variance). Scale bar = 20 μm in B. 
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